Adult-onset Still's disease presenting with generalized seizures in the absence of macrophage activation syndrome: a case report with review of the neurological literature
DOI:
https://doi.org/10.18203/2349-3933.ijam20263727Keywords:
Adult Onset Still's disease, Seizures, Hyperferritinemia, Yamaguchi Criteria, Neurological reviewAbstract
Adult-onset Still’s disease (AOSD) is a rare systemic autoinflammatory disorder characterized by quotidian fever, arthritis, rash, and marked hyperferritinemia. Neurological manifestations are uncommon, and generalized seizures are exceptionally rare, particularly in the absence of macrophage activation syndrome (MAS). An 18-year-old man presented with one month of high-grade fever, migratory polyarthralgia, cervical and axillary lymphadenopathy, mild hepatosplenomegaly, and two generalized tonic-clonic seizures preceding diagnosis. Laboratory evaluation showed neutrophilic leukocytosis (21,300/mm³), elevated ESR and CRP, transaminitis, and serum ferritin >2,000 ng/mL. Electrolytes were normal. Blood and urine cultures, HIV testing, tuberculosis evaluation, echocardiography, thoracic CT, and lymph-node cytology were unremarkable. NCCT brain showed no structural lesion, and there was no clinical or laboratory evidence of MAS. After exclusion of infectious, autoimmune, and malignant causes, the patient fulfilled Yamaguchi criteria for AOSD. Treatment with prednisolone (1 mg/kg/day), methotrexate, and levetiracetam resulted in rapid resolution of fever and improvement in arthralgia. Generalized seizures may rarely be the presenting manifestation of AOSD even without MAS or demonstrable CNS pathology. In patients with unexplained seizures accompanied by persistent systemic inflammation and marked hyperferritinemia, AOSD should be considered after exclusion of infectious, autoimmune, and structural neurological causes; early immunosuppressive therapy is associated with favorable outcomes.
Metrics
References
Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol. 2018;14(10):603-18. DOI: https://doi.org/10.1038/s41584-018-0081-x
Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still's disease. J Autoimmun. 2018;93:24-36. DOI: https://doi.org/10.1016/j.jaut.2018.07.018
Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheumatol. 2008;22(5):773-92. DOI: https://doi.org/10.1016/j.berh.2008.08.006
Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol. 1992;19(3):424-30.
Ruscitti P, Cipriani P, Masedu F. Adult-onset Still’s disease: Evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med. 2016;14(1):194. DOI: https://doi.org/10.1186/s12916-016-0738-8
Le AN, Gudushauri N, Tan IJ, Bhat R, Khan R. Atypical adult-onset Still's disease presenting with seizures and myocarditis complicated by macrophage activation syndrome. Cureus. 2024;16(2):e52635.
Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still’s disease. Ann Rheum Dis. 2006;65(5):564-72. DOI: https://doi.org/10.1136/ard.2005.042143
Fautrel B, Borget C, Rozenberg S, Meyer O, Le Loët X, Masson C, et al. Corticosteroid-sparing effect of methotrexate in adult Still's disease. J Rheumatol. 1999;26(2):373-8.
Cavalli G, Dinarello CA. Anakinra therapy for non-cancer inflammatory diseases. Front Pharmacol. 2018;9:1157. DOI: https://doi.org/10.3389/fphar.2018.01157
Kedor C, Wittkowski H, Foell D. Canakinumab in adult-onset Still’s disease: results from a randomized, double-blind, placebo-controlled, multicentre, prospective phase II study. Ther Adv Musculoskelet Dis. 2021;13:1-14.
Laskari K, Tzioufas AG, Mavragani CP. Adult-onset Still's disease: from pathophysiology to targeted therapies. Clin Exp Rheumatol. 2022;40(6):1032-9.
Colafrancesco S, Priori R, Alessandri C. IL-1 inhibition in adult-onset Still’s disease: canakinumab versus anakinra in a single-centre retrospective study. Clin Exp Rheumatol. 2019;37(121):57-63.
Kaneko Y, Kameda H, Ikeda K, Tomonoti I, Kosaku M, Hyota T, et al. Tocilizumab in patients with adult-onset Still’s disease refractory to glucocorticoids: a randomized, double-blind, placebo-controlled phase III trial. Mod Rheumatol. 2021;31(5):944-52.
Ichida H, Kawaguchi Y. Clinical manifestations of adult-onset Still’s disease: a review of 57 cases. Mod Rheumatol. 2012;22(1):53-9.
Ruscitti P, Cipriani P, Ciccia F. Efficacy and safety of biologic agents in adult-onset Still’s disease: a systematic literature review. Autoimmun Rev. 2017;16(11):1036-45.
Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still's disease. Autoimmun Rev. 2014;13(7):708-22. DOI: https://doi.org/10.1016/j.autrev.2014.01.058
Kadavath S, Efthimiou P. Adult-onset Still's disease-pathogenesis, clinical manifestations, and new treatment options. Ann Med. 2015;47(1):6-14. DOI: https://doi.org/10.3109/07853890.2014.971052
Vastert SJ, Jamilloux Y, Quartier P. Pathogenesis of adult-onset Still’s disease: current understanding and recent insights. Expert Rev Clin Immunol. 2021;17(8):787-803.
Efthimiou P, Kontzias A, Hur P, Rodha K, Ramakrishna GS, Nakasato P. Adult-onset Still's disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. Semin Arthritis Rheum. 2021;51:858-74. DOI: https://doi.org/10.1016/j.semarthrit.2021.06.004
Zhao M, Wu D, Shen M. Adult-onset Still’s disease with neurological involvement: a single-centre report. Rheumatology (Oxford). 2021;60(9):4152-7. DOI: https://doi.org/10.1093/rheumatology/keaa899
Dabadghao VS, Sharma SK, Mangudkar SS, Garg SA. Seizures in a patient of adult onset Still’s disease. Med J Dr. D. Y. Patil Univ. 2014;7(3):400-2. DOI: https://doi.org/10.4103/0975-2870.129010
Le AN, Fort DJ, Raychaudhuri SP. Atypical Adult-Onset Still’s Disease Presenting with Seizures and Myocarditis Complicated by Macrophage Activation Syndrome: A Case Report. Cureus. 2024;16(1):e52635. DOI: https://doi.org/10.7759/cureus.52635
Kim JY, Sunwoo L, Lee KG. Brain microhemorrhages in adult-onset Still’s disease: a case report. Medicine (Baltimore). 2025;104(16):e42127. DOI: https://doi.org/10.1097/MD.0000000000042127
Li XF, Ker AK, Liao HL. Adult-onset Still’s disease presenting with aseptic meningitis: a case report. Front Immunol. 2025;16:1660434. DOI: https://doi.org/10.3389/fimmu.2025.1660434
Zhao Y, Liu Q, Pan J, Momoh Ol. Stormy Course of Adult-Onset Still’s Disease with Macrophage Activation Syndrome and Concurrent Membranoproliferative Glomerulonephritis: A Case Report. Cureus. 2023;15(10):e107638.
Nishida T, Suzuki K, Kuwada N, Nakamura Y, Motoyoshi K, Kamakura K. Hemophagocytic syndrome and adult Still’s disease associated with meningoencephalitis and unconsciousness. Intern Med. 2001;40(10):1037-040. DOI: https://doi.org/10.2169/internalmedicine.40.1037
Zhao M, Shen M. Adult-onset Still’s disease presenting with aseptic meningitis: a case report and literature review. Clin Med Insights Arthritis Musculoskelet Disord. 2023;16:11795441231195636. DOI: https://doi.org/10.1177/11795441231195636
Desai SS, Allen E, Deodhar AA. Miller Fisher syndrome in adult-onset Still’s disease: case report and review of the literature. J Rheumatol. 2014;41(2):216-22. DOI: https://doi.org/10.1093/rheumatology/41.2.216
Mariana Santos, Daniela R, Helder S, Catarina P, Catarina C, Rodrigo R, et al. Neurological manifestations of adult-onset Still's disease: case-based review. Clinical Rheumatology. 2021;40(1):407-11. DOI: https://doi.org/10.1007/s10067-020-05244-8
Young G, Azam ST, Olesya G, Kristina K. Neuropsychiatric manifestations in adult-onset Still's disease. BMJ Case Reports. 2020;13(9):e235956. DOI: https://doi.org/10.1136/bcr-2020-235956
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Archit Kalra, Poonam Gupta, Ajeet Kumar Chaurasia, Divya Chutani

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.